Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SAN DIEGO, Dec. 13, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.2 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 28,800,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 14,400,000 shares of common stock at an exercise price of $0.26 per share for a term of four years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering are expected to be approximately $7.2 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $6.5 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Dawson James Securities, Inc. acted as the exclusive placement agent for the transaction.  Burrill LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.

The offering is expected to close on December 17, 2012, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
(Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
(Date:10/30/2014)... Oct. 29, 2014   ViaDerma, Inc. ... bringing new products to market, is committed to ... has developed an innovative, patent-pending dual carrier transdermal ... of pharmaceutical active ingredients to penetrate the skin ... therapy. The transdermal delivery method also overcomes microbial ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... 1b study planned for mid 2008 with Phase 2 development ... to begin late in 2008 or in early ... NUVO ) today announced positive results from the Phase 1,proof-of-concept ... offset of anticoagulation after,a single bolus dose with a favorable safety ...
... Erythematosus ... ... (Nasdaq: RIGL ) announced today that its lead product,candidate, R788, ... reported in a recently published,study of the drug candidate. R788 (fostamatinib ...
Cached Medicine Technology:Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 2Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 3Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 4Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 2Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 3Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 4
(Date:10/30/2014)... Chicago, IL (PRWEB) October 30, 2014 Dr. ... launched a new website for his practices; OB GYN ... Chicago, IL . This website contains important information about ... covers as well as downloadable patient forms in English and ... use and the service pages on the website provide Dr. ...
(Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
(Date:10/30/2014)... who used stem cells to create miniature human stomachs ... new way to learn more about the development and ... pluripotent stem cells -- which can become any type ... functional miniature stomachs, to study infection by H. ... stomach cancer. The miniature stomachs offer many research ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
(Date:10/29/2014)... women at first acted surprised. Some insisted the blood tests ... not used the study products assigned to them as participants ... likely consequence, did not find any of the three products ... were among 127 former VOICE participants who, as part of ... in in-depth interviews and/or focus group discussions after learning the ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
... of hormone worsened respiratory disease , , THURSDAY, Nov. 20 ... may explain why women with cystic fibrosis tend to ... at the University of North Carolina report. , , ... 20 issue of the Journal of Clinical Investigation ...
... Reno,s Downtown Ballroom was transformed into a Cirque style extravaganza ... ballroom to help raise funds for one of Reno,s most ... residents and many of Nevada,s prominent leaders, including Nevada Governor ... To view the Multimedia News Release, go to: ...
... Nov. 20 Precyse Solutions, the leader in,driving ... management solutions, was recognized by the Eastern Technology,Council ... at the 16th,Enterprise Award Gala held at the ... top technology and life sciences companies and entrepreneurs. ...
... at risk for hospital visits of their own , , THURSDAY, ... for a loved one with Alzheimer,s results in 25 percent ... hospital visit every six months, says an Indiana University study. ... an Alzheimer,s patient is difficult, but the Indiana University researchers ...
... Quality Care , ARLINGTON HEIGHTS, Ill., Nov. 20 ... cannot afford to cut corners on quality of care, warns ... thing to temporarily substitute fillers for facelifts, ASPS says the ... professional training. This concern was discussed recently at the ASPS ...
... People are often reluctant to undergo a routine but ... be fatal. According to the American Cancer Society, colon ... American men and women and kills about 50,000 Americans ... cancer have no symptoms or family history," says Prof. ...
Cached Medicine News:Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 3Health News:Photos: Nevada's Saint Mary's Regional Medical Center Raises $1.3 Million During Centennial Soiree 2Health News:Precyse Solutions Honored as 'Technology Company of the Year' 2Health News:When the Caregiver Becomes the Patient 2Health News:Caution Urged as Patients Seek Deals on Cosmetic Surgery 2Health News:A simple blood test for colon cancer 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
Medicine Products: